Courtney D. DiNardo, MD
Disclosures: Membership on advisory committees or review panels, board membership, etc.-Agios -|Membership on advisory committees or review panels, board membership, etc.-Celgene-|Membership on advisory committees or review panels, board membership, etc.-Abbvie-|Stocks or stock options, excluding diversified mutual funds-Notable Labs-|Honoraria-Novartis AG-|Honoraria-Aprea-|Honoraria-Gilead-|Honoraria-Foghorn Therapeutics- - 06/25/2021

Dr. DiNardo is an academic clinical researcher with a primary focus on individualized therapy and precision oncology for myeloid malignancies, including the optimal incorporation of genomics into standard risk assessments and treatment algorithms, and the clinical evaluation of targeted therapeutics for molecularly-defined patient subgroups. 

 

Dr. DiNardo has experience in designing, overseeing, and executing successful clinical trials; from Phase 1 dose-finding studies, to innovative investigator-initiated Phase II trials, to confirmatory Phase III trials.  Dr. DiNardo has served an integral role in several highly influential trials involving IDH1, IDH2 and BCL2 inhibitors, which have led to the FDA approval of three therapies in AML since 2017 (the first-in-class IDH2 inhibitor enasidenib, the IDH1 inhibitor ivosidenib, and the BCL2 inhibitor venetoclax in combination with hypomethylating agents).